

**Adequate vs. deep response to UDCA in PBC: to what extent and under what conditions  
is normal ALP level associated with complication-free survival gain?**

Christophe Corpechot<sup>1</sup>, Sara Lemoine<sup>1</sup>, Pierre-Antoine Soret<sup>1</sup>, Bettina Hansen<sup>2,3</sup>, Gideon Hirschfield<sup>3</sup>, Aliya Gulamhusein<sup>3</sup>, Aldo J. Montano-Loza<sup>4</sup>, Ellina Lytvyak<sup>5</sup>, Albert Pares<sup>6</sup>, Ignasi Olivas<sup>6</sup>, John E. Eaton<sup>7</sup>, Karim T. Osman<sup>7</sup>, Christoph Schramm<sup>8</sup>, Marcial Sebode<sup>8</sup>, Ansgar W. Lohse<sup>8</sup>, George Dalekos<sup>9</sup>, Nikolaos Gatselis<sup>9</sup>, Frederik Nevens<sup>10</sup>, Nora Cazzagon<sup>11</sup>, Alessandra Zago<sup>11</sup>, Francesco Paolo Russo<sup>11</sup>, Annarosa Floreani<sup>11</sup>, Nadir Abbas<sup>12</sup>, Palak Trivedi<sup>13</sup>, Douglas Thorburn<sup>14</sup>, Francesca Saffioti<sup>14</sup>, Laszlo Barkai<sup>14</sup>, Davide Roccarina<sup>14</sup>, Vicenza Calvaruso<sup>15</sup>, Anna Fichera<sup>15</sup>, Adèle Delamarre<sup>16</sup>, Natalia Sobenko<sup>17</sup>, Alejandra Maria Villamil<sup>17</sup>, Esli Medina-Morales<sup>18</sup>, Alan Bonder<sup>18</sup>, Vilas Patwardhan<sup>18</sup>, Cristina Rigamonti<sup>19</sup>, Marco Carbone<sup>20</sup>, Pietro Invernizzi<sup>20</sup>, Laura Cristoferi<sup>20</sup>, Adriaan van der Meer<sup>21</sup>, Rozanne de Veer<sup>21</sup>, Ehud Zigmond<sup>22</sup>, Eyal Yehezkel<sup>22</sup>, Andreas E. Kremer<sup>23</sup>, Ansgar Deibel<sup>23</sup>, Tony Bruns<sup>24</sup>, Karsten Große<sup>24</sup>, Aaron Wetten<sup>25</sup>, Jessica Katharine Dyson<sup>25</sup>, David Jones<sup>25</sup>, Jérôme Dumortier<sup>26</sup>, Georges-Philippe Pageaux<sup>27</sup>, Victor de Lédinghen<sup>16</sup>, Olivier Chazouillères<sup>1</sup>, and Fabrice Carrat<sup>28</sup> on behalf of the Global & ERN Rare-Liver PBC Study Groups

(1) Reference Center for Inflammatory Biliary Diseases and Autoimmune Hepatitis, European Reference Network on Hepatological Diseases (ERN Rare-Liver), Saint-Antoine Hospital,

Assistance Publique - Hôpitaux de Paris; Inserm UMR\_S938, Saint-Antoine Research Center, Sorbonne University, Paris, France; (2) Department of Epidemiology & Biostatistics, Erasmus MC, Rotterdam, the Netherlands; (3) Toronto Centre for Liver Disease, University Health Network, University of Toronto, Toronto, Canada; (4) Division of Gastroenterology and Liver Unit, University of Alberta, Edmonton, Canada; (5) Division of Preventive Medicine, University of Alberta, Edmonton, Alberta, Canada; (6) Liver Unit, Hospital Clinic, University of Barcelona, The August Pi i Sunyer Biomedical Research Institute, Biomedical Research Networking Center in Hepatic and Digestive Diseases, European Reference Network on Hepatological Diseases (ERN Rare-Liver), Barcelona, Spain; (7) Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, USA; (8) Department of Medicine I and Martin Zeitz Center for Rare Diseases, European Reference Network on Hepatological Diseases (ERN Rare-Liver), University Medical Center Hamburg–Eppendorf, Hamburg, Germany; (9) Department of Medicine and Research Laboratory of Internal Medicine, National Expertise Center of Greece in Autoimmune Liver Diseases, European Reference Network on Hepatological Diseases (ERN Rare-Liver), General University Hospital, Larissa, Greece; (10) Division of Hepatology and Liver Transplantation, European Reference Network on Hepatological Diseases (ERN Rare-Liver), University Hospitals KU, Leuven, Belgium; (11) Department of Surgery, Oncology and Gastroenterology, European Reference Network on Hepatological Diseases (ERN Rare-Liver), University of Padova, Padova, Italy; (12) Liver Unit, University Hospitals Birmingham National Health Service Foundation Trust Queen Elizabeth, Birmingham, United Kingdom; (13) National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre (BRC), Institute of Immunology and Immunotherapy, Centre for Liver and Gastrointestinal Research, University of Birmingham, Birmingham B15 2TT, United Kingdom; (14) University College London Institute for Liver and Digestive Health, Royal Free Hospital, London, United Kingdom; (15)

Section of Gastroenterology and Hepatology, PROMISE, University of Palermo, Palermo, Italy; (16) Department of Hepatology, University Hospitals of Bordeaux, Pessac, France; (17) Department of Hepatology & Liver Transplantation, Italian Hospital of Buenos Aires, Argentina; (18) Department of Medicine, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, USA; (19) Department of Internal Medicine, Università del Piemonte Orientale, Novara, Italy; (20) Division of Gastroenterology, Center for Autoimmune Liver Diseases, Department of Medicine and Surgery, European Reference Network on Hepatological Diseases (ERN Rare-Liver), University of Milano-Bicocca, Monza, Italy; (21) Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands; (22) The Research Center for Digestive Tract and Liver Diseases, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; (23) Department of Gastroenterology and Hepatology, University Hospital Zürich, Zürich, Switzerland; (24) Department of Medicine III, University Hospital RWTH Aachen, European Reference Network on Hepatological Diseases (ERN Rare-Liver), Aachen, Germany; (25) Department of Hepatology and Liver Transplantation, Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, United Kingdom; (26) Department of Gastroenterology and Hepatology, Edouard Herriot Hospital, Hospices Civils de Lyon, Claude Bernard University, Lyon, France; (27) Department of Hepatology and Liver Transplantation, University Hospital, Montpellier, France; (28) Public Health Unit, Saint-Antoine Hospital, Assistance Publique – Hôpitaux de Paris; Pierre Louis Institute of Epidemiology and Public Health, Sorbonne University, Inserm, Paris, France.

### **Conflicts of Interest**

Christophe Corpechot consults and received grants from Intercept. He received grants from Arrow. He has other interests with Biotest and Gilead. Sara Lemoine consults for Albireo.

Bettina Hansen consults, advises, and received grants from Albireo, Calliditas Therapeutics, CymaBay, Intercept, and Mirum. Consults and advises HighTide, Ipsen, and Pliant. Gideon Hirschfield consults and is one the speakers' board for Ipsen. He consults for CymaBay, Intercept, and Plaintiff. He is on the speakers' bureau for GlaxoSmithKline. Aliya Gulamhusein consults and is one the speakers' board for Advanz. She consults for CymaBay. Albert Pares consults for Calliditas Therapeutics, Intercept, and Kowa. Frederik Nevens consults for Calliditas Therapeutics, CymaBay, Intercept, and Mayoly. Francesco Paolo Russo is on the speakers' bureau for AbbVie and Gilead. Annarosa Floreani consults and received grants from Advanz. Nadir Abbas is on the speakers' bureau and received grants from Advanz. He is on the speakers' bureau for Dr Falk Pharma. Vicenza Calvaruso advises, is on the speakers' bureau, and received grants from Advanz. She consults and is on the speakers' bureau for AbbVie. She advises Ipsen. She is on the speakers' bureau for Echosens. She received grants from Gilead. Alan Bonder consults and received grants from CymaBay and Intercept. He received grants from Chemobab-101, Gilead, Mirium, and Vistas. He has other interests with Dynamed and Up to Date. Pietro Invernizzi Advises and received grants from Intercept. He advises Zydus. He received grants from AbbVie. Laura Cristoferi received grants from Albireo. She is on the speakers' bureau for Advanz and Echosens. Adriaan van der Meer consults for and is on the speakers' bureau for AOP Health. He is on the speakers' bureau and received grants from Zambon. He consults for Intercept. He is on the speakers' bureau for AbbVie. He received grants from CymaBay and Gilead. Andreas E. Kremer consults, advises, is on the speakers' bureau, and received grants from Intercept. He consults, advises, and is on the speakers' bureau for AbbVie, Bayer, CymaBay, Gilead, GlaxoSmithKline, and MSD. He is on the speakers' bureau for AOP Orphan, Beiersdorf, Bristol Myers Squibb, CMS, Eisai, Escient, Falk, FMC, Guidepoint, Janssen, Lilly, Medscape, Mirum, Myr, Newbridge, Novartis, Roche, Viofor, and Zambon. Tony Bruns Consults for Advanz, Grifols, and Sobi.

He has other interests with CSL Behring, Falk Foundation, Gilead, and Gore. Jessica Katharine Dyson is on the speakers' bureau and received grants from Falk Pharma and GlaxoSmithKline. She consults for NICE. She received grants from Umecrine. David Jones consults, advises, is on the speakers' bureau, and received grants from Intercept. He consults for Ipsen and Umecrine. He is on the speakers' bureau for Advanz, Falk Pharma, and GlaxoSmithKline. The remaining authors have no conflicts to report.

**Running title:** Significance of normal ALP in PBC

**Keywords:** Primary biliary cholangitis; ursodeoxycholic acid; ALP; Prognosis; Second-line therapy.

**Summary word count:** 250

**Manuscript word count (excluding abstract, references, and figure legends):** 3453

**Number of references:** 22

**Number of Tables:** 4

**Number of Figures:** 3

**Supplementary Tables (Supporting Information):** 11

**Supplementary Figures (Supporting Information):** 5

**Financial support:** No study funding.

**List of abbreviations:**

ALP, alkaline phosphatase.

ALT, alanine aminotransferase.

AST, aspartate aminotransferase.

CI, confidence interval.

GGT, gamma-glutamyl transpeptidase.

HR, hazard ratio.

LSM, liver stiffness measurement.

LT, liver transplantation.

PBC, primary biliary cholangitis.

RMST, restricted mean survival time.

RMTL, restricted mean time lost.

UDCA, ursodeoxycholic acid.

ULN, upper limit of the normal range.

VCTE, vibration-controlled transient elastography.

**Contact Information:**

Christophe Corpechot, MD. Reference center for inflammatory biliary diseases and autoimmune hepatitis, Saint-Antoine Hospital, Assistance Publique – Hôpitaux de Paris; Inserm UMR\_S938, Saint-Antoine Research Center, Sorbonne University; 184 rue du faubourg Saint-Antoine, 75571 Paris, Cedex 12, France. Email: christophe.corpechot@aphp.fr.

## graphical abstract

### GA1

#### Abstract

##### Background and Aims:

Normal alkaline phosphatase (ALP) levels in ursodeoxycholic acid (UDCA)-treated patients with primary biliary cholangitis (PBC) are associated with better long-term outcome.

However, second-line therapies are currently recommended only when ALP levels remain above 1.5 times the upper limit of normal (xULN) after 12-month UDCA. We assessed whether, in patients considered good responders to UDCA, normal ALP levels were associated with significant survival gains.

##### Approach and Results:

We performed a retrospective cohort study of 1,047 patients with PBC who attained an adequate response to UDCA according to Paris-2 criteria. Time to liver-related complications, liver transplantation or death was assessed using adjusted restricted mean survival time analysis. The overall incidence rate of events was 17.0 (95%CI 13.7 – 21.1) per 1,000 out of 4,763.2 patient-years. On the whole population, normal serum ALP values (but not normal GGT, ALT, or AST; or total bilirubin < 0.6 xULN) were associated with an overall absolute complication-free survival gain at 10 years of 7.6 months (95%CI 2.7 – 12.6,  $p=0.003$ ). In subgroup analysis, this association was significant in patients with a liver stiffness measurement  $\geq 10$  kPa and/or age  $\leq 62$  years, with a 10-year absolute complication-free survival gain of 52.8 months (95%CI 45.7 – 59.9,  $p<0.001$ ) when these two conditions were met.

##### Conclusions:

PBC patients with an adequate response to UDCA and persistent ALP elevation between 1.1 and 1.5 xULN, particularly those with advanced fibrosis and/or who are sufficiently young, remain at risk of poor outcome. Further therapeutic efforts should be considered for these patients.

ACCEPTED



## Introduction

Primary biliary cholangitis (PBC) is a slowly progressive, chronic cholestatic liver disease that, if not adequately treated, can lead to cirrhosis and its complications and therefore expose patients to excess mortality or the need for liver transplantation (LT) [1]. Its standard treatment is lifelong oral administration of ursodeoxycholic acid (UDCA), which improves biochemical features of cholestasis and long-term survival [2-4]. However, approximately a third of patients, primarily those with an inadequate biochemical response to this treatment, remains at significant risk of liver-related complications and premature death [5-7]. For those inadequate responders, second-line therapies, including obeticholic acid or fibrates, are able to improve biochemical response rates and potentially long-term clinical outcomes [8-11]. Currently, these adjunctive treatments are only considered when serum alkaline phosphatase (ALP) values remain above 1.5 (or 1.67 depending on the criteria used to define inadequate response) times the upper limit of normal (xULN) or total bilirubin is elevated after 12 months of UDCA therapy [12-14].

Very recently, it has been shown that, even in patients with an adequate response to UDCA, normal ALP levels or total bilirubin  $\leq 0.6$  xULN could be associated with a further reduction in the risk of death or LT [15, 16]. However, the significance of this deep biochemical response in terms of absolute clinical benefit, i.e., real gains in complication-free life expectancy, and not just risk reduction, needs to be further assessed. Indeed, it remains unclear whether UDCA-treated patients with moderate persistent ALP elevation (i.e., between 1.0 and 1.5 xULN) or a bilirubin value between 0.6 and 1.0 xULN should potentially be considered for second-line therapy. Therefore, the aim of the present study was to evaluate, in a large population of PBC patients who had achieved an adequate response to UDCA over the past 15 years, the complication-free survival gain associated with a deep biochemical response.

## Patients and methods

### *Study population and design*

This was an international multicentre retrospective cohort study involving 24 tertiary centres in 13 countries in Europe, North and South America, and the Middle East. The characteristics of the original cohort from which this study was drawn have recently been published [17]. As this cohort was specifically set up to evaluate the prognostic value of liver stiffness measurement (LSM) assessed by vibration-controlled transient elastography (VCTE, Fibroscan), all patients were initially selected on the basis of at least one available LSM. To be eligible for the current study, the patients in this cohort had to meet the following criteria: 1) long-term treatment with UDCA of  $\geq 12$  months; 2) no second-line therapy, including obeticholic acid, fibrates (bezafibrate, fenofibrate, or others) or corticosteroids (including budesonide); 3) no diagnosis of autoimmune hepatitis-PBC overlap syndrome; 4) no signs of decompensated cirrhosis at entry; 5) at least one occurrence of adequate biochemical response as defined by the Paris-2 criteria (i.e., ALP and AST levels  $\leq 1.5$  xULN, and total bilirubin normal) after 12 months of UDCA therapy, the first occurrence defining the landmark (time zero) for survival analysis. All available blood test results over time in the same patient were taken into account. Fibrosis stage was defined at entry based on LSM as follows: advanced fibrosis stage, LSM  $\geq 10$  kPa; non-advanced fibrosis stage, LSM  $< 10$  kPa [18].

The study was conducted in accordance with the Declaration of Helsinki. It was a retrospective observational analysis based on previously collected routine care data with no expressed opposition by patients. The protocol was approved by the institutional research board of each participating centre in accordance with their local regulations.

### *Statistical analysis*

The primary end point was survival without serious clinical events, defined as death, LT, or severe liver-related complications, including variceal bleeding, ascites, hepatic encephalopathy, and hepatocellular carcinoma, when no death or LT was recorded at time of last follow-up. Because 95% of patients had follow-up  $\leq 11$  years after entry into observation (i.e., from time zero), survival data were right-censored at 10 years.

We first performed a Cox proportional hazards regression analysis to identify among all standard biochemical liver tests the simple binary conditions (i.e.,  $ALP \leq 1.0 \times ULN$ ,  $GGT \leq 1.0 \times ULN$ ,  $ALT \leq 1.0 \times ULN$ ,  $AST \leq 1.0 \times ULN$ , and total bilirubin  $\leq 0.6 \times ULN$ ) that could be associated with prolonged survival. These conditions were assessed as time-dependent categorical variables and models were adjusted for age, sex, duration of UDCA therapy, LSM, albumin level, total bilirubin level, and platelet count, with the latter 4 variables studied as continuous time-dependent variables. The proportional hazards assumption was tested based on the Schoenfeld residuals. To test for potential delayed entry bias (i.e., left censoring), a Cox model with late entry, defined as the time between 1 year of UDCA and entry into the cohort, was evaluated in parallel. In addition, we performed two sensitivity analyses by changing the primary end point as follows: 1) liver-related (and not all-cause) deaths, LT, or liver-related complications; 2) all-cause deaths or LT. Unadjusted and adjusted hazard ratios (HRs) and corresponding confidence intervals (CIs) were calculated for each condition evaluated. For those that remained significantly associated with survival in adjusted analysis, the relationship between HR and the biochemical variable was assessed in a continuous way using a fractional polynomial function.

To determine the absolute clinical benefit (i.e., gross gain in life expectancy), the liver test conditions associated with improved survival in Cox analysis were next studied using restricted mean survival time (RMST) and restricted mean time lost (RMTL) non-parametric analyses. These methods of survival analysis determine absolute (difference in RMST) and

relative (RMST ratio) gains in event-free survival time at a given horizon, as well as a HR equivalent (RMTL ratio). As for Cox analyses, all analyses were adjusted for age, sex, duration of UDCA therapy, LSM, albumin level, total bilirubin level, and platelet count to control for the main prognostic and confounding factors. With the exception of sex, all of these variables were studied as continuous parameters assessed at entry. A truncation time of 10 years was specified, which corresponded to the minimum of the largest observed event time among groups. Because age and LSM were independently associated with complication-free survival gains in multivariable-adjusted RMST, analyses were subsequently stratified by these 2 parameters, whose optimal discriminating thresholds (62 years and 10 kPa, respectively) were determined using receiver-operating characteristic analysis with the Youden index.

Survival curves were constructed using Kaplan-Meier estimates and compared using the log-rank test. All tests were two-tailed and a p-value < 0.05 was considered significant. Statistical analyses were performed using Stata 14.1 (Stata Corp LLC).

## Results

A total of 1,047 patients in the original cohort met the eligibility criteria (i.e., had pure non-decompensated PBC with an adequate biochemical response to UDCA alone according to the Paris-2 criteria) for the study (**Figure S1**). The number of participating centres and countries is shown in the Supporting Information (**Tables S1 & S2**). The study population at entry was predominantly female over the age of 45 years with normal total bilirubin level, normal or moderately elevated levels of liver enzymes, and low LSM as evaluated by VCTE (**Table 1**). The mean duration of UDCA therapy at entry was 7.8 years. The proportions of patients at entry with elevated levels of ALP, GGT, ALT, and AST were 34%, 50%, 17% and 14%, respectively. One third had total bilirubin level > 0.6 xULN and 17% had advanced

fibrosis by LSM. A comparison with the excluded patient population is shown in Table S3. The study population was older, with lower bilirubin and liver enzyme levels, and a lower proportion of patients with advanced LSM disease.

A total of 81 serious clinical events occurred during 4,763.2 person-years of observation, including 58 deaths, of which 16 were liver-related, 18 cirrhotic complications without death or LT at last visit, including 12 ascites, 3 hepatocellular carcinomas, 2 variceal bleedings, and 1 hepatic encephalopathy, and 5 LT. The incidence rate of these events was 17.0 (95% CI 13.7 – 21.1) per 1,000 person-years for the entire cohort, 10.9 (8.1 – 14.7) per 1,000 person-years for patients with non-advanced fibrosis at entry, and 46.4 (33.8 – 63.8) per 1,000 person-years for those with advanced fibrosis at entry.

In a non-adjusted Cox regression analysis with a time-dependent variable, the 2 liver test conditions that significantly associated with improved complication-free survival at any time were an ALP value  $\leq 1.0$  xULN (HR 0.46, 95% CI 0.27 – 0.77) and a total bilirubin level  $\leq 0.6$  xULN (HR 0.58, 95% CI 0.38 – 0.96). After adjustment for time-dependent survival factors and duration of UDCA therapy, the only biochemical condition associated with complication-free survival was a normal ALP level (aHR 0.57, 95% CI 0.27 – 0.99) (**Table 2**). The results remained consistent when a delayed-entry survival model was applied to control for survival bias (**Table S4**) or when different definitions of the primary end point were used (**Table S5**, **Table S6**). The complication-free survival curves of patients with or without normal ALP levels at entry are shown in **Figure 1**. The 10-year complication-free survival rate was 85.7% (95% CI 77.7% – 91.0%) for patients with normal ALP levels at entry and 73.2% (95% CI 61.5% – 81.9%) for those without (log-rank test,  $p < 0.001$ ). The relationship between the HR and the ALP level at entry is shown in **Figure 2**. Between 0.9 xULN and 1.5 xULN, the log HR increased as a linear function of the ALP level, indicating the exponential prognostic value of ALP in this range.

The complication-free survival curves associated with the other liver test conditions are shown in the Supporting Information (**Figure S2**). Compared to normal ALP levels, a complete biochemical response with normal ALP, GGT, AST, and ALT was not associated with higher survival rates (**Figure S3**). Furthermore, patients with normal ALP levels had similar survival rates whether total bilirubin was  $\leq$  or  $>$  0.6 xULN (**Figure S4**). The relationship between the HR and total bilirubin level at entry is shown in **Figure S5**.

The absolute and relative gains in complication-free survival associated with normal ALP levels at baseline were then determined using RMST analysis. In a univariate analysis, an ALP level  $\leq$  1.0 xULN at entry was associated with an overall absolute complication-free survival gain at 10 years of 6.9 months (95% CI 2.6 – 11.1 months,  $p=0.002$ ) corresponding to a relative complication-free survival gain of 6.4% (95% CI 2.3% – 10.6%,  $p=0.002$ ). After controlling for prognostic factors and duration of UDCA treatment, these gains were 7.6 months (95% CI 2.7 – 12.6 months,  $p=0.003$ ) and 7.2% (95% CI 2.3% – 12.4%,  $p=0.004$ ), respectively, and were associated with an overall HR (time-lost ratio) of 0.44 (95% CI 0.29 – 0.65,  $p<0.001$ ) (**Table 3**). Because age and LSM were independently associated with gains in complication-free survival associated with normal ALP levels, the analyses were subsequently stratified by these 2 parameters.

When stratified according to the optimal LSM threshold (10 kPa) at entry, absolute and relative complication-free survival gains associated with normal ALP levels were greater in patients in the high-LSM group (19.4 months, 95% CI 6.9 – 31.8 months,  $p=0.002$  and 20.0%, 95% CI 3.2% – 39.6%,  $p=0.018$ , respectively) than in the low-LSM group (5.7 months, 95% CI 1.1 – 10.2 months,  $p=0.015$  and 5.1%, 95% CI 0.9% – 9.6%,  $p=0.018$ , respectively) (**Table S7**). The estimated complication-free survival functions for normal and abnormal ALP groups according to LSM threshold at entry are shown in **Figure 3**. Gains in complication-free survival were also stratified according to the optimal age threshold (62 years). While

absolute and relative complication-free survival gains related to normal ALP levels were significant in younger patients, they were not in older patients (**Table S8**). When LSM and age conditions were considered together, the patients with the greatest gains in complication-free survival were those (8%) who were both younger and had higher LSM, in whom absolute and relative gains at 10 years were 52.8 months (95% CI 45.7 – 59.9,  $p < 0.001$ ) and 138.9% (95% CI 130.5% – 147.6%,  $p < 0.001$ ), respectively. Those (52%) who met only one condition among young age and high LSM had significant intermediate gains in complication-free survival, and those (40%) who met neither condition had no significant gains despite a significant decrease in HR (**Tables 4**). Consistent results were obtained when different definitions of the primary end point were used (**Table S9**, **Table S10**).

## Discussion

In this large retrospective cohort study of patients with pure PBC and adequate biochemical response to UDCA followed up over the past 15 years, normal ALP levels were associated with significant absolute and relative gains in complication-free survival at 10 years, particularly in patients with advanced fibrosis ( $LSM \geq 10$  kPa) and/or younger age ( $\leq 62$  years). These results suggest that PBC patients previously considered as adequate responders to UDCA but with moderate persistent ALP elevation, i.e., one third of them, may benefit from therapeutic escalation with second-line therapies, as fibrates or obeticholic acid, especially younger patients with advanced compensated disease (nearly 10% of this population), in whom the survival benefit associated with normal ALP values is greatest.

In a previous study based on older data [15], bilirubin levels  $\leq 0.6$  xULN or normal ALP values were associated with the lowest risk of death or LT in PBC, with a 10% and 7% reduction, respectively, in 10-year LT-free survival. However, the actual survival gain associated with this risk reduction was not evaluated, nor was the interactions with liver

fibrosis extension and age, thus limiting the clinical interpretability of these data. In the present study, we used RMST analysis, which is an alternative that can overcome some of the limitations of proportional hazards modelling [19]. Difference in RMST, the mean absolute difference of event-free time until a milestone time point, does not depend on model assumptions and helps determine whether a benefit is clinically meaningful, as opposed to the relative information provided by the HR. Using this, we show that patients who attained normal ALP values had overall 8 additional months of life free of serious clinical events at 10 years (i.e., approximately 7% relative gain), a result that increased to 19 months (20% relative gain) for patients with advanced fibrosis and to 53 months (i.e., more than 4 years over 10 years of follow-up) for those with both advanced fibrosis and age  $\leq 62$  years at entry. Of note, similar significant differences were found when the composite end point was restricted to liver-related events, thus limiting the risk of a possible confounding effect of ALP reduction on extrahepatic mortality, particularly cardiometabolic mortality. The results were also consistent when only death or LT was considered. In addition, we found that, between 0.9 xULN and 1.5 xULN, i.e., in a relatively low range of ALP values, the HR increased as an exponential function of ALP level. All these results support the use of normal ALP values as a primary therapeutic endpoint goal, most notably in younger patients with PBC and elevated LSM.

In contrast to Murillo Perez et al [15], we did not find total bilirubin levels  $\leq 0.6$  xULN as an independent predictor of long-term outcomes. The fact that this condition was found to be associated with improved complication-free survival in univariate but not multivariate analysis, and that patients at the upper end of the normal range for total bilirubin appeared to have an increased HR, may suggest a lack of statistical power and insufficient follow-up, particularly in patients with advanced disease, who represented only a small proportion of the study population. Unlike the study by Murillo Perez et al, all patients in our study were



adequate responders to UDCA and thus had normal bilirubin levels at entry, a situation that may have reduced the prognostic range of this variable. It would have been meaningful to study conjugated rather than total bilirubin levels, because bilirubin conjugates are likely to better reflect the severity of PBC and may be more closely related to its prognosis [20]. Unfortunately, this parameter, which is often overlooked in routine practice, especially in patients with normal bilirubin level, was not available in our database.

We also found no significant associations in this specific cohort between normal levels of aminotransferases or GGT and long-term prognosis. It should be noted, however, that patients diagnosed with an autoimmune hepatitis overlap syndrome, or alternatively, the inflammatory PBC phenotype, both of which usually require combination therapies and corticosteroids, had been excluded from the study, and only a small minority of patients at entry had elevated ALT or AST levels. As a consequence, we do not exclude that our results on aminotransferases may be due to a lack of statistical power. Half of the patients had elevated GGT levels at entry. Normal GGT in this population was not associated with a better clinical outcome. This contrasts with the findings of Gerussi et al, who suggested that in patients with low ALP level, a GGT level  $> 3.2$  xULN may identify those who might require treatment optimization [21]. In our study, GGT was only slightly elevated, with an average level at entry of 2.45 xULN in those with an abnormal test.

Our results are consistent with those of Harms et al. suggesting that the absolute clinical benefit from UDCA therapy in patients with PBC is greater for those with the most advanced disease [22]. Indeed, we found that both absolute and relative gains in complication-free survival associated with normal ALP values were greater in patients with advanced fibrosis, as evaluated with VCTE, than in those with less severe disease. This result is not unexpected since PBC is a slowly progressive disease and the effect of a treatment on hard clinical end points, such as LT, death, or liver decompensations over a limited observation period is more

likely to be observed in the late stages than in the early stages of the disease. Nevertheless, our study suggests that therapeutic goals in PBC, especially in terms of biochemical response and ALP reduction, should be more stringent for patients with extensive fibrosis, in particular cirrhosis.

These results also highlight that a significant decrease in HR is not necessarily clinically relevant when considering specifically a slowly progressive disease with few long-term clinical events, as PBC is, particularly in patients with adequate response to UDCA. Indeed, whereas normal ALP values in this population were consistently associated with a significant decrease in HR in the different subgroups studied, a concrete clinical benefit (i.e., a significant increase in life expectancy without complications) was mainly found in the youngest patients, i.e., before the age of 62 years, or those with high LSM, i.e.,  $\geq 10$  kPa, who together account for 60% of the study population. This inverse relationship between age and prognostic value of ALP under UDCA has been recently suggested [16]. The added value of a second line therapy in PBC is likely to decrease with age, particularly beyond 70, especially if any ALP elevation is considered as a potential indication regardless of disease stage. It also depends, of course, on the relationship between the drug's safety profile and its expected benefits. The point is that hepatologists should be proactive in identifying at-risk PBC patients (before or during treatment) and treating well generally, to achieve the best overall outcomes. In this regard, ALP level under UDCA, LSM, and age are undoubtedly key elements for therapeutic decision making in PBC.

Our study has several limitations. Because of its retrospective design, and although analyses were adjusted for major prognostic factors and duration of UDCA treatment, and survival bias was accounted for by using delayed-entry models, we cannot fully exclude the misleading effects of selection biases and undetected confounders. Of course, this population with adequate response to UDCA was made up of older, less severely affected patients. If we

could control for duration of UDCA exposure, we were unable to do the same for the dose, nor could we control for other confounders such as metabolic-associated fatty liver disease or alcohol consumption. Data completeness was not optimal for some of the parameters analyzed and the low number of events may limit the accuracy and generalizability of the findings. It was also not possible to look for a center effect because of the large number of centers and the low number of events per center. Finally, because the original cohort from which this study was conducted was initially designed to evaluate in PBC the prognostic role of LSM by VCTE, a device primarily available in Western tertiary centers, this cohort might not be fully representative of a PBC real-world population.

In conclusion, among PBC patients with an adequate response to UDCA, those who achieve normal ALP values have a significantly longer life expectancy without liver complications than patients who do not. This survival advantage associated with normal ALP is particularly noticeable in younger patients with advanced fibrosis. Therefore, additional therapeutic efforts should be considered in UDCA-treated PBC patients with persistent ALP elevations between 1.1 and 1.5 xULN, particularly in those with advanced disease and/or sufficiently young age.

**Table 1. Baseline characteristics of the patients.**

	<b>Obs.</b>	<b>Mean/Freq.</b>	<b>Std.</b>	<b>Min</b>	<b>Max</b>
			<b>Dev./Percent</b>		
Year of entry	1047	2013.93	3.92	2004	2021
Age at entry (years)	1047	60.63	11.63	23.1	92.5
Age at entry ≤ 45 years	1047	113	10.79	-	-
Age at diagnosis (years)	869	51.79	11.51	22.0	87.4
Female gender	1047	950	90.74	-	-
Time spent on UDCA (years)	1047	7.83	5.91	1.0	32.7
T. Bilirubin (mg/dl)	1047	0.48	0.23	0.1	1.0
T. Bilirubin > 0.6 xULN	1047	339	32.41	-	-
ALP (xULN)	1047	0.89	0.28	0.2	1.5
ALP > 1.0 xULN	1047	360	34.38	-	-
GGT (xULN)	841	1.53	1.64	0.1	15.2
GGT > 1.0 xULN	841	424	50.42	-	-
AST (xULN)	1047	0.76	0.24	0.1	1.5
AST > 1.0 xULN	1047	149	14.24	-	-
ALT (xULN)	1043	0.72	0.37	0.1	3.5
ALT > 1.0 xULN	1043	176	16.87	-	-
Albumin (g/l)	940	42.16	3.45	26.6	51.1
Albumin < 1.0 xLLN	940	25	2.66	-	-
Platelets (G/l)	1008	243.92	76.08	29.0	620.0
Platelets < 1.0 xLLN	1008	105	10.42	-	-
LSM (kPa)	1047	7.66	5.88	2.0	74.5
LSM ≥ 10 kPa	1047	180	17.19	-	-

**Table 2. Time-dependent Cox regression analyses for each liver test condition evaluated.**

<b>Unadjusted analysis</b>						
	<b>Haz. Ratio</b>	<b>Std. Err.</b>	<b>z</b>	<b>P&gt; z </b>	<b>[95% Conf.</b>	<b>Interval]</b>
ALP $\leq$ 1.0 xULN	0.457	0.120	-2.98	0.003	0.273	0.765
T. Bilirubin $\leq$ 0.6 xULN	0.581	0.147	-2.14	0.032	0.353	0.955
AST $\leq$ 1.0 xULN	0.599	0.193	-1.59	0.111	0.319	1.126
GGT $\leq$ 1.0 xULN	0.707	0.202	-1.21	0.225	0.404	1.237
ALT $\leq$ 1.0 xULN	1.524	0.581	1.10	0.269	0.722	3.218
<b>Adjusted analysis</b>						
	<b>Haz. Ratio</b>	<b>Std. Err.</b>	<b>z</b>	<b>P&gt; z </b>	<b>[95% Conf.</b>	<b>Interval]</b>
ALP $\leq$ 1.0 xULN	0.578	0.159	-2.00	0.046	0.226	0.990
T. Bilirubin $\leq$ 0.6 xULN	0.513	0.285	-1.20	0.230	0.172	1.526
AST $\leq$ 1.0 xULN	0.569	0.267	-1.20	0.230	0.226	1.430
GGT $\leq$ 1.0 xULN	0.885	0.273	-0.40	0.692	0.484	1.620
ALT $\leq$ 1.0 xULN	0.883	0.573	-0.19	0.848	0.247	3.152

Results were ranked by decreasing level of statistical significance. The proportional hazard assumption was verified for each liver test evaluated (Supporting Information, **Table S3**).

**Table 3. Adjusted 10-year restricted mean complication-free survival time analysis for ALP level  $\leq 1.0$  xULN at entry (n=914).**

	Mean	Std. Err.	z	P> z	[95% Conf.	Interval]
Difference in RMST (months)	7.620	2.520	3.02	0.003	2.664	12.564
Ratio of RMST (relative gain)	1.072	0.027	2.89	0.004	1.023	1.124
Ratio of RMTL (hazard ratio)	0.437	0.111	-4.03	0.000	0.293	0.654

RMST, restricted mean survival time. RMTL, restricted mean time lost. Difference in RMST is the absolute survival gain. Ratio of RMST is the relative survival gain. Ratio of RMTL is the hazard ratio.

ACCEPTED

**Table 4. Adjusted 10-year restricted mean complication-free survival time analysis for ALP level  $\leq 1.0$  xULN at entry stratified by age and LSM.**

<b>2 conditions met among age <math>\leq 62</math> years and LSM <math>\geq 10</math> kPa (n=67)</b>						
	<b>Mean</b>	<b>Std. Err.</b>	<b>z</b>	<b>P&gt; z </b>	<b>[95% Conf.</b>	<b>Interval]</b>
Difference in RMST (months)	52.812	3.180	14.51	0.000	45.672	59.940
Ratio of RMST (relative gain)	2.389	0.043	47.61	0.000	2.305	2.476
Ratio of RMTL (hazard ratio)	0.003	0.001	-21.78	0.000	0.001	0.004
<b>Only 1 condition met among age <math>\leq 62</math> years and LSM <math>\geq 10</math> kPa (n=477)</b>						
	<b>Mean</b>	<b>Std. Err.</b>	<b>z</b>	<b>P&gt; z </b>	<b>[95% Conf.</b>	<b>Interval]</b>
Difference in RMST (months)	8.928	3.576	2.49	0.013	1.908	15.948
Ratio of RMST (relative gain)	1.085	0.036	2.36	0.018	1.014	1.160
Ratio of RMTL (hazard ratio)	0.429	0.185	-2.71	0.007	0.233	0.792
<b>No conditions met among age <math>\leq 62</math> years and LSM <math>\geq 10</math> kPa (n=373)</b>						
	<b>Mean</b>	<b>Std. Err.</b>	<b>z</b>	<b>P&gt; z </b>	<b>[95% Conf.</b>	<b>Interval]</b>
Difference in RMST (months)	1.812	3.504	0.52	0.603	-5.040	8.676

Ratio of RMST (relative gain)	1.013	0.034	0.40	0.691	0.951	1.079
Ratio of RMTL (hazard ratio)	0.486	0.124	-3.47	0.001	0.323	0.730

---


RMST, restricted mean survival time. RMTL, restricted mean time lost. Difference in RMST is the absolute survival gain. Ratio of RMST is the relative survival gain. Ratio of RMTL is the hazard ratio.

ACCEPTED




**Figure 1. Complication-free survival curves of patients with or without normal ALP levels at entry.**

The Kaplan-Meier curve and its 95% confidence interval for the normal ALP group are in gray and light gray, respectively. Those for the abnormal ALP group are in black and dark gray, respectively. The p-value corresponds to the log-rank test.




**Figure 2. The hazard ratio for death, liver transplantation or liver complications as a function of ALP level at entry.**

Each circle corresponds to a patient. The regression curve and its 95% confidence interval are in black and light gray, respectively. The ordinate scale for hazard ratio is logarithmic.



**Figure 3. Estimated complication-free survival functions for the normal- and abnormal-ALP groups depending on LSM at entry.**

Kaplan-Meier curves for the normal ALP group are in thin lines. Those for the abnormal ALP group are in thick lines. Kaplan-Meier curves for the lower LSM group are in gray. Those for the higher LSM group are in black



## References

1. Lleo A, Wang GQ, Gershwin ME, Hirschfield GM. Primary biliary cholangitis. *Lancet* 2020;396:1915-1926.
2. Poupon RE, Balkau B, Eschwege E, Poupon R. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. *N Engl J Med* 1991;324:1548-1554.
3. Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. *Gastroenterology* 1997;113:884-890.
4. Harms MH, van Buuren HR, Corpechot C, Thorburn D, Janssen HLA, Lindor KD, Hirschfield GM, et al. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. *J Hepatol* 2019;71:357-365.
5. Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. *Gastroenterology* 2006;130:715-720.
6. Corpechot C, Abenavoli L, Rabahi N, Chretien Y, Andreani T, Johanet C, Chazouilleres O, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. *Hepatology* 2008;48:871-877.
7. Lammers WJ, van Buuren HR, Hirschfield GM, Janssen HL, Invernizzi P, Mason AL, Ponsioen CY, et al. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. *Gastroenterology* 2014;147:1338-1349.

8. Nevens F, Andreone P, Mazzella G, Strasser SI, Bowlus C, Invernizzi P, Drenth JP, et al. A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. *N Engl J Med* 2016;375:631-643.
9. Corpechot C, Chazouilleres O, Rousseau A, Le Gruyer A, Habersetzer F, Mathurin P, Goria O, et al. A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis. *N Engl J Med* 2018;378:2171-2181.
10. Tanaka A, Hirohara J, Nakano T, Matsumoto K, Chazouilleres O, Takikawa H, Hansen BE, et al. Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis. *J Hepatol* 2021;75:565-571.
11. **Murillo Perez CF, Fisher H**, Hiu S, Kareithi D, Adekunle F, Mayne T, Malecha E, et al. Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls. *Gastroenterology* 2022;163:1630-1642 e1633.
12. Hirschfield G, Beuers U, Corpechot C, Invernizzi P, Jones D, Marzioni M, Schramm C. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. *J Hepatol* 2017;67:145-172.
13. Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. *Hepatology* 2019;69:394-419.
14. Hirschfield GM, Dyson JK, Alexander GJM, Chapman MH, Collier J, Hubscher S, Patanwala I, et al. The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines. *Gut* 2018;67:1568-1594.
15. Murillo Perez CF, Harms MH, Lindor KD, van Buuren HR, Hirschfield GM, Corpechot C, van der Meer AJ, et al. Goals of Treatment for Improved Survival in Primary Biliary

Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase. *Am J Gastroenterol* 2020;115:1066-1074.

16. de Veer RC, Harms MH, Corpechot C, Thorburn D, Invernizzi P, Janssen HLA, Battezzati PM, et al. Liver transplant-free survival according to alkaline phosphatase and GLOBE score in patients with primary biliary cholangitis treated with ursodeoxycholic acid. *Aliment Pharmacol Ther* 2022;56:1408-1418.
17. Corpechot C, Carrat F, Gaouar F, Chau F, Hirschfield G, Gulamhusein A, Montano-Loza AJ, et al. Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis. *J Hepatol* 2022;77:1545-1553.
18. Corpechot C, Carrat F, Poujol-Robert A, Gaouar F, Wendum D, Chazouilleres O, Poupon R. Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis. *Hepatology* 2012;56:198-208.
19. Kloecker DE, Davies MJ, Khunti K, Zaccardi F. Uses and Limitations of the Restricted Mean Survival Time: Illustrative Examples From Cardiovascular Outcomes and Mortality Trials in Type 2 Diabetes. *Ann Intern Med* 2020;172:541-552.
20. Jansen PL, Peters WH, Janssens AR. Clinical value of serum bilirubin subfractionation by high-performance liquid chromatography and conventional methods in patients with primary biliary cirrhosis. *J Hepatol* 1986;2:485-494.
21. **Gerussi A, Bernasconi DP**, O'Donnell SE, Lammers WJ, Van Buuren H, Hirschfield G, Janssen H, et al. Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis. *Clin Gastroenterol Hepatol* 2021;19:1688-1697 e1614.

22. Harms MH, de Veer RC, Lammers WJ, Corpechot C, Thorburn D, Janssen HLA, Lindor KD, et al. Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis. *Gut* 2020;69:1502-1509.

#### **Author contributions:**

Dr. C. Corpechot is acting as the submission's guarantor.

Authors contributions: CC, study co-designer, coordinating investigator, data acquisition, data analysis and interpretation, drafting manuscript; FC: statistical analysis, data interpretation, critical revision; VL, study co-designer, data acquisition, critical revision; Remaining authors: data acquisition, critical revision. All authors approved the final version of the manuscript.

#### **Conflicts of interest:**

Dr. Corpechot reports receiving grants from Arrow and Intercept France, consulting fees from Intercept France, Inventiva Pharma, Cymabay and Genkyotex, and fees for teaching from Intercept France and GlaxoSmithKline France; Dr. Chazouillères, receiving grant support from Aptalis, fees for teaching from Mayoly Spindler, consulting fees from Genfit, and fees for teaching and consulting fees from Intercept; Dr. Schramm, receiving lecture fees from Falk Pharma; Dr. Dumortier, receiving consulting and teaching fees from Intercept France; Dr Dyson, receiving speaker fees from Dr Falk and Intercept and consultation fees from NICE; Dr. Montano-Loza, receiving lectures and advisory board fees from Intercept and consulting fees from Genfit; Dr. Parés, receiving grant funding, speaking fees, and advisory board fees from Intercept, advisory board fees and speaking fees from Novartis, advisory board fees from Genfit and Calliditas Therapeutics, and speaking fees from CymaBay and Inova Diagnostics.; Dr. Kremer, receiving advisory board and speaking fees from Advanz,

CymaBay, Falk, Intercept, and GSK; Dr. Bruns reports receiving advisory board fees from Intercept, Grifols and Sobi and receiving speaking fees from Falk Foundation, Abbvie, CSL Behring, Intercept, Merck, Gore and Gilead; Dr. Trivedi, receiving institutional salary support from the NIHR Birmingham BRC, grant support from the Wellcome Trust, the Medical Research Foundation, LifeArc, GSK, Guts UK, PSC Support, Intercept Pharma, Dr. Falk Pharma, Gilead sciences, and Bristol Myers Squibb, speaker fees from Albireo, Intercept, Ipsen and Dr Falk, and advisory board/consultancy fees from Albireo, Intercept, Ipsen Dr. Falk and GSK; Dr Villamil, receiving speaking fees from Intercept and Abbvie, consulting fees from Celnova Pharma and advisory board fees from Intercept and Novartis; No other potential conflict of interest relevant to this article was reported.

ACCEPTED